NY-MOODY'S-ANALYTICS
10.6.2019 08:32:06 CEST | Business Wire | Press release
Moody's Analytics has announced the launch of the Certification of Professional Competence in Mortgage Lending in Hungary, in collaboration with the Budapest Institute of Banking (BIB) and the International Training Center for Bankers (ITCB).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190609005060/en/
The certification program meets the requirements of the European
Parliament and Council Directive on Mortgage Credit. The objective of
the mandate is to ensure a minimum standard of competency and ethics
among mortgage lenders, specifically applicable to the following roles:
-
Bank professionals in the front, middle and back office engaged in
residential mortgage lending (for example, product design, underwriting,
administration and management, as well as selling)
- Mortgage
brokers who propose, offer, and/or sell residential mortgages
-
Managers of employees listed above
- Individuals aspiring to work
in any position related to the Hungarian mortgage market
Beyond meeting regulatory requirements, the program is designed to elevate the consultative skills of lending professionals and help them become responsible advisers to their customers, in line with the objectives of Hungarian banks and the evolving expectations of the market.
The program delivers a modern learning experience by using advanced technology to personalize the learning and expedite the impact while minimizing the workload for those who already possess the required skills.
Gergely Fábián, Chief Executive Officer of BIB, noted, “We are delighted to work with Moody’s Analytics and to bring their educational framework and professional knowledge in mortgage lending to Hungary. The program aims to instill best practices in lending for mortgage lenders in the Hungarian Banking industry.”
Béla Öcsi, Chief Executive Officer of the ITCB, added, “The innovative Credit Coach framework from Moody’s Analytics brings an enhanced learning experience for all participants. We are pleased to be able to deliver substantial value to the local banking sector through the collaboration with BIB and Moody’s Analytics.”
“We are honored to collaborate with the BIB and ITCB to deliver a program that represents the highest standards in international credit practices, adapted to the unique context of the Hungarian banking industry,” added Ari Lehavi, Executive Director at Moody’s Analytics. “We look forward to supporting similar institutes across the region in their goal of addressing the certification requirements of the European Mortgage Credit Directive, as applicable in their local market.”
Moody’s Analytics recently collaborated with the Hellenic Banking Institute to offer the Certification of Professional Competence in Mortgage Lending program in Greece.
Click here to learn more about Moody’s Analytics Learning Solutions, including Credit Coach.
About Moody’s Analytics
Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter or LinkedIn .
Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 42 countries.
About the Budapest Institute of Banking
The foundation of the Budapest Institute of Banking (BIB) is rooted in the matching of market needs with the social responsibility objectives of the Magyar Nemzeti Bank (the Central Bank of Hungary) and the Budapest Stock Exchange.
A modern education centre has been created where up-to-date knowledge is transferred in the form of experience-based learning. Forms of edutainment are an integral part of the teaching methodology. Covering the entire operational range of the banking, financial, and insurance sector, the courses grant the opportunity to participants, from experts to top managers, to gain cutting-edge knowledge and to discover professional development opportunities.
The BIB aims to train experts who will be able to address the challenges of the future.
For more information please visit our website: https://www.bib-edu.hu/en .
About International Training Center for Bankers (ITCB)
Founded 30 years ago, ITCB has been providing quality financial education and specialized risk consultancy services for the banking sector in Hungary, Central and Eastern Europe and the Middle East. Building on its long track record and synergies between advisory and training, ITCB’s current offering focuses on tailor-made case study-driven banking seminars, e-learning courses and financial simulations. For more information about ITCB, visit our website .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190609005060/en/
Contact:
KATERINA SOUMILOVA Moody’s Analytics Communications +1.212.553.1177
Moody's Analytics Media Relations
moodysanalytics.com twitter.com/moodysanalytics linkedin.com/company/moodysanalytics
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom